Short Interest in Virios Therapeutics, Inc. (NASDAQ:VIRI) Decreases By 33.9%

Virios Therapeutics, Inc. (NASDAQ:VIRI) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 579,800 shares, a decline of 33.9% from the July 15th total of 877,700 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Maxim Group initiated coverage on Virios Therapeutics in a research report on Thursday, June 20th. They set a “buy” rating and a $1.00 target price on the stock. HC Wainwright dropped their price target on Virios Therapeutics from $0.40 to $0.20 and set a “neutral” rating on the stock in a research note on Friday, August 9th.

Virios Therapeutics Trading Up 7.6 %

NASDAQ VIRI traded up $0.01 on Thursday, hitting $0.19. 171,175 shares of the company’s stock traded hands, compared to its average volume of 851,374. The firm has a market capitalization of $3.64 million, a PE ratio of -0.70 and a beta of 1.61. Virios Therapeutics has a 1-year low of $0.16 and a 1-year high of $1.37. The firm’s 50-day moving average price is $0.23 and its two-hundred day moving average price is $0.33.

Virios Therapeutics (NASDAQ:VIRI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. During the same quarter last year, the firm posted ($0.08) EPS. On average, research analysts anticipate that Virios Therapeutics will post -0.27 earnings per share for the current fiscal year.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.